News & events

Webinars

Webinars

Previous Webinars

JUNE 21st, 2022

Overcoming the challenges in deploying new imaging biomarkers in clinical trials – Perspectives from patients, physicians and other stakeholders

This webinar is jointly organized by Labcorp Drug Development and Median Technologies. New Imaging biomarkers have a strong potential to provide additional insight for clinical trials: better selection of patients, prediction of response to therapy, early assessments of drug effects and safety. However, implementing them in clinical trials often promote challenges. The aim of this webinar is to discuss these challenges from the perspective of patients, physicians and the different stakeholders involved in the oncology clinical trials. During this webinar, you will learn:

  • The value of modern imaging technologies in oncology trials
  • The challenges linked to implementation of new imaging biomarkers
  • How AI powered imaging optimizes clinical trial design

Presenters

  • Dr Yumin Zhang, Vice President and Chief Medical Officer, Huayi Technology CO LTD
  • Dr Ravi Karra, M.D, Senior Medical Director Oncology, Labcorp Drug Development
  • Dr Yan Liu, Chief Medical Officer, Median Technologies.
APRIL 7, 2022

Effective collaboration between imaging CRO and investigator sites contributes to successful clinical trials

Investigator sites have an instrumental role in clinical trials, with endless responsibilities such as recruiting patients, acquiring, and submitting medical images to imaging CROs. Imaging CROs such as Median Technologies, will collect and review medical images to assess drug safety and efficacy based on the imaging endpoints. Efficient communication and streamlined processes between investigator sites and imaging CROs are key success factors for clinical trials in oncology. During this 45min presentation, we will address the following key points:

  • Describe site and image management activities,
  • Discuss guidelines for reviewing investigator site feedback,
  • Identify the main challenges,
  • Describe tools that Median has implemented to optimize collaboration with investigator sites.

Presenters

  • Narvy Pao, Site Manager, Median Technologies
  • Reagan Moore, Image Manager, Median Technologies
FEBRUARY 1, 2022

Discuss the 4 main causes of variability in centralized oncology radiological assessments

Inter-reader variability can create challenges in oncology trial results. During this 45-minute presentation, Median Technologies addresses the 4 main causes of variability occurring during RECIST1.1 assessment and describes control strategies using data analytics and medical investigations. During this presentation, you will:

  • Discover the most common types of reader discrepancies in oncology follow-up
  • Learn how to control the causes of variability in centralized independent review and how to prevent them
  • Grasp how we at Median Technologies, handle inter-reader variability through our methods and strategies

Presenters

  • Antoine Iannessi, Medical Director, Median Technologies
  • Emilie Serres, Clinical Research Scientist, Median Technologies
NOV 23, 2021

Imaging in oncology trials: can it help to make “go or no go” decisions?

This webinar is jointly organized by Labcorp Drug Development and Median Technologies. During our presentation, Labcorp and Median’s experts discuss modern imaging biomarkers covering the most important cancer hallmarks such as cell death, metabolism, vascularity, and hypoxia, and explain how they could be used in oncology trials for early response assessment and disease management.

Presenters

  • Pr Laure Fournier, Academic Radiologist, AP-HP, Assistance Publique-Hôpitaux de Paris, France
  • Dr Ravi Karra, M.D, Senior Medical Director Oncology, Labcorp Drug Development
  • Dr Yan Liu, Chief Medical Officer, Median Technologies